Related Experiment Videos

Preventive HIV-1 vaccines: where are we going?

¹AIDS Pathogenesis Research Unit, Macfarlane Burnet Centre for Medical Research, Fairfield, Vic, Australia.

International Journal of STD & AIDS

|January 5, 1999

Summary

No abstract available in PubMed .

Keywords:

Acquired Immunodeficiency Syndrome--prevention and control Diseases Economic Factors Hiv Infections--prevention and control Progress Report Research And Development Technology Vaccines Viral Diseases World

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4+/CD8+ T cells and humoral responses in macaques.

Scientific reports·2020

Induction of vaginal-resident HIV-specific CD8 T cells with mucosal prime-boost immunization.

Mucosal immunology·2017

Morbidity and in-hospital mortality after hip fracture surgery on weekends versus weekdays.

Journal of orthopaedic surgery (Hong Kong)·2016

Functional advantage of educated KIR2DL1(+) natural killer cells for anti-HIV-1 antibody-dependent activation.

Clinical and experimental immunology·2015

Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase-mediated CD16 cleavage after anti-HIV antibody-dependent activation.

Clinical and experimental immunology·2015

Antiretroviral therapy initiation in an Australian cohort: implications for increased use of antiretroviral therapy.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2014

See all related articles